Publicador de contenidos

Investigación e Innovación Programas

GAMA

Development of Novel Gastrointestinal Biomarkers for Use in HIV Incidence Determination in a Sub-Saharan African Setting

Foto: Photo: César Velasco

The earliest phase of HIV infection is clinically important in determining the natural history of disease. It is also the moment in which much of the immune damage occurs and constitutes the most infectious stage of the infection. Development of a test which could distinguish between individuals with early or longstanding HIV infection could potentially be used for clinical management, but would also allow the estimation of an HIV incidence rate.

The primary aim of GAMA is to gain a better understanding of dynamics of biomarkers of gastrointestinal inflammation during the first year of HIV infection as compared to chronic infection. The tremendous damage inflicted on the gut-associated lymphoid tissue during early HIV infection may provide the opportunity to identify biomarkers which present altered expression during the early phases of HIV infection. GAMA will assess the utility of these markers for identifying recent HIV infection as well as for potential associations with progression to AIDS. Understanding the dynamics of these biomarkers and associating them with standard serological responses during early HIV infection may reveal specific changes in expression patterns of biomarkers which are able to distinguish early from longstanding HIV infection.

Development of an assay for measuring HIV incidence would facilitate the evaluation of ongoing prevention programs as well as the design and implementation of trials to evaluate new prevention interventions.

Project Funders

Main Funders: Bill & Mellinda Gates Foundation

Co-funding: Ministry of Economy and Competitiveness. Government of Spain

Nuestro equipo

Principal Investigator (PI)

  • Denise Suzanne Naniche
    Denise Suzanne Naniche

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

MAMAH

Improving Maternal and Infant Health by reducing malaria risks in African women: evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

ICARIA

Improving Care through Azithromycin Research for Infants in Africa

PreFIT

Predicting the Future: Incipient Tuberculosis

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)

TwinAir

Digital Twins Enabled Indoor Air Quality Management for Healthy Living

ENDÈMIC

Community knowledge generation through scientific culture, urban ecology and art

EpiGen

Building Scalable Pathogen Genomic Epidemiology in Ethiopia

Hepatitis C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

FLAVOBAC

Nuevas moléculas de oro coordinadas con flavonoides contra bacterias patógenas multirresistentes prioritarias